'I expect India to be concerned about US pharma tariffs': Rubio on Trump's 200% storm
The United States announced a phased tariff schedule for generic drug imports: zero tariff for a two-year grace period from 1 August 2026, rising to 100% from August 2028, and further to 200% from August 2029.
The US Secretary of State stated that the issue of these generic drug tariffs did not come up during his discussions with India's External Affairs Minister in Manila, though he noted it may have been raised separately with other US administration officials.
The Secretary of State said he expects India to be concerned about the tariff plan, given India's position as a major supplier of generic medicines to the US market.
The announcement is separate from an existing 100% Section 232 tariff on certain patented pharmaceutical imports (effective from 31 July 2026), from which generic and biosimilar drugs are currently exempted.
Both governments reaffirmed their intent to conclude an interim bilateral trade agreement, with talks ongoing on market access, non-tariff barriers, and digital trade.
Section 232 Tariff Authority — Trade Expansion Act, 1962
Section 232 of the US Trade Expansion Act, 1962 allows the President to impose trade restrictions, including tariffs, on imports found to threaten US national security, based on an investigation conducted by the Department of Commerce.
Key Details
- The Department of Commerce's Bureau of Industry and Security initiated a Section 232 investigation into pharmaceutical and pharmaceutical-ingredient imports in April 2026, citing US dependence on foreign-made drugs and active pharmaceutical ingredients (APIs) as a national-security risk.
- Based on this investigation, a 100% Section 232 tariff on certain patented pharmaceutical imports took effect from 31 July 2026, with exemptions for generics, biosimilars, and companies with US manufacturing/pricing commitments.
- The newly announced generic-drug-specific tariff (0% until August 2026, 100% from August 2028, 200% from August 2029) is a separate, phased schedule intended to incentivise US-based ("onshored") generic drug manufacturing before penalties escalate.
- Section 232 tariffs are distinct from Section 301 tariffs (used for unfair trade practices) and from reciprocal/IEEPA-based tariffs used elsewhere in US trade policy.
The Secretary of State's remarks concern this generic-drug-specific tariff track, which — unlike the existing patented-drug Section 232 tariff — directly targets the segment (generics) that dominates India's pharmaceutical exports to the US.
India's Pharmaceutical Exports and the "Pharmacy of the World" Role
India is one of the largest global suppliers of generic medicines, and the US is its single largest pharmaceutical export destination, making it acutely exposed to any US tariff action on generics.
Key Details
- India's total pharmaceutical exports were valued at approximately $25.8 billion, of which about $9.7–10.5 billion (roughly 37–38%) went to the United States.
- Indian companies are estimated to supply a very large share — often cited near half — of generic medicines consumed in the US market.
- Generic drug imports are difficult to isolate precisely in US customs data, as they fall under the same HS code (3004) as patented and branded medicines; industry estimates, not customs classification, are typically used to size the generics trade.
Because the bulk of India's US-bound pharma exports are generics rather than patented drugs, the newly announced generic-tariff schedule (not the existing patented-drug Section 232 tariff) is the more consequential threat to India's pharmaceutical trade.
India-US Interim Trade Agreement Framework
India and the US have been negotiating an interim bilateral trade agreement since early 2026, running in parallel with sector-specific US tariff actions like the pharmaceutical measures.
Key Details
- A framework for the interim agreement was jointly announced in February 2026, envisioning a reduction in US tariffs on Indian goods from 25% to 18%, alongside Indian commitments to reduce tariffs on US industrial and agricultural goods and to expand purchases of US energy products, aircraft, and technology.
- Ministerial-level talks (Commerce Minister-level from India, US Trade Representative-level from the US) continued through mid-2026 on market access, digital trade, and non-tariff barriers, without full resolution of outstanding issues.
- Sector-specific tariff actions (such as the Section 232 pharmaceutical tariffs) are typically negotiated and applied outside the interim trade agreement's core tariff schedule, meaning pharma tariffs can proceed even as the broader interim deal talks continue.
The Secretary of State's statement that pharma tariffs were not discussed with India's External Affairs Minister — but reaffirmation of intent to conclude the interim trade deal — illustrates how sector-specific tariff tracks and the broader bilateral trade negotiation can move on separate diplomatic channels.
- Generic drug tariff schedule: 0% from 1 August 2026 (two-year grace period); 100% from August 2028; 200% from August 2029
- Existing Section 232 tariff on patented pharmaceuticals: 100%, effective 31 July 2026 (generics/biosimilars exempted)
- Legal basis for pharma tariffs: Section 232, Trade Expansion Act, 1962 (national security investigation initiated April 2026)
- India's pharma exports to the US: approximately $9.7–10.5 billion, about 37–38% of India's total pharma exports (~$25.8 billion)
- India-US interim trade agreement framework: announced February 2026; proposes reducing US tariffs on Indian goods from 25% to 18%